ClinicalTrials.gg
RecruitingNCT06025409Updated Sep 6, 2023

Evaluate the Efficacy and Safety of DWJ108J

A Phase 3 interventional study of Leuprolide Acetate 11.25 MG/ML in Central Precocious Puberty, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
4 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Planned enrollment
6th of 14
79 · median 68
Started
2023
the only one that year
Phase 3
6 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
2 of 14
Daewoong Pharmaceutical Co. LTD.

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 13th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 4 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.

Read the detailed description

The drug in this study is called leuprorelin. It is administered as a 3 month subcutaneous depot injection. Leuprorelin is used to treat children who have Central Precocious Puberty. This study will look at whether leuprorelin can stop early Central Precocious Puberty.

03

Conditions studied

  • Central Precocious Puberty

Browse trials for

04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Exhibited pubertal response of LH (peak ≥ 5 IU/L) during GnRH stimulation test at screening
  2. Diagnosis of central precocious puberty
  3. For boys, those under 10 years old and for girls, those under 9 years old, based on Visit 2 (Enrollment), with Tanner Stage 2 or above
  4. Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year
  5. In cases where the legal guardian of the child listened to the explanation of this clinical trial and provided written consent

Exclusion criteria

Exclusion Criteria:

  1. Following conditions at Visit 1(Screening) :

    Conditions related to pseudo precocious puberty, Incomplete precocious puberty, Dysfunction of pituitary, adrenal, thyroid, or reproductive glands, Growth disorders or bone diseases that could affect bone growth, Brain tumor, Pituitary adenoma

  2. requires treatment within 6 months of receiving a registration number during the trial period that could affect the hypothalamic-pituitary-gonadal axis
  3. Prior treatment with GnRH analogues
  4. Hypersensitive to the drug for this clinical trial or GnRH analogues
  5. Prior or current therapy with growth hormone
  6. has taken the following medications within 8 weeks of Visit 1 (Screening): Sex hormone medications, Sex hormone antagonists, (local application is allowed; oral formulations are not allowed if taken within 3 days continuously, and use within 2 weeks of screening is prohibited), Herbal medicine
  7. Meets the following criteria based on screening test results:

    , ALT levels exceed twice the , Creatinine levels exceed 1.5 times the upper limit of normal, Bone age is above 11.5 years

  8. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (estimated)

Study arms

  • Experimental
    Experimental: Leuprorelin

    Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (\<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months.

    Drug: Leuprolide Acetate 11.25 MG/ML

Interventions

  • DrugLeuprolide Acetate 11.25 MG/ML

    Drug page: Leuprolide

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.

    Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L.

    Time frame: 6 months

Secondary outcomes

  1. Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 3 Months.

    Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L.

    Time frame: 3 months

  2. Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration.

    Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration.

    Time frame: Baseline, 3 and 6 months

  3. Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration

    Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration

    Time frame: 3 and 6 months

  4. Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration.

    Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration.

    Time frame: Baseline, 3 and 6 months

  5. Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration.

    Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration.

    Time frame: 6 months

  6. Average Tanner Stage at 6 months after administration, and the changes compared to before administration.

    Average Tanner Stage at 6 months after administration, and the changes compared to before administration.

    Time frame: 6 months

  7. Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration.

    Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Feb 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 6, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Feb 28, 2025
CompletionEst.
Aug 31, 2025
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06025409
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Aug 1, 2023
Primary completion
Feb 28, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Sep 6, 2023

Study contacts

Yeonseo Choi, MD. PhD
Contact
yeonseo@daewoong.co.kr
82-2-550-8800
Jin Soong Hwang, MD. PhD
principal investigator · Ajou University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion